Array BioPharma Nyarita, binimetinib, Braftovi, encorafenib, Mektovi, Pfizer
Encorafenib sareng binimetinib disatujuan ku FDA pikeun pengobatan kanker paru sél non-leutik métastatik kalayan mutasi BRAF V600E
Administrasi Pangan sareng Narkoba (FDA) nyatujuan Encorafenib (Braftovi, Array BioPharma Inc., anak perusahaan milik Pfizer) sareng binimetinib (Mektovi, Array BioPharma Inc.) dina bulan Nopémber 2023 salaku ubar anu tiasa dianggo pikeun t..
Bosulif, Bosutinib, leukemia myelogenous kronis, CML, Pfizer
Bosutinib disatujuan ku FDA pikeun penderita murangkalih sareng leukemia myelogenous kronis
Nov 2023: Pikeun penderita murangkalih umur sataun ka luhur sareng fase kronis (CP) Ph+ leukemia myelogenous kronis (CML), boh anu nembe didiagnosis (ND) atanapi tahan atanapi teu toleran (R / I) kana terapi sateuacana, Administrasi Pangan sareng Narkoba. .
Pfizer, TALAPRO-2, Talazoparib
Talazoparib sareng enzalutamide disatujuan ku FDA pikeun kanker prostat tahan metastatik metastatik HRR gen-mutasi.
July 2023: The Food and Drug Administration cleared talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene mutations in metastatic castration-resistant prostate cancer (mCRPC). TALAP..
ADVL0912, limfoma kinase anaplastik, lymphoma, NCT00939770, Pfizer, Xalkori
Crizotinib disatujuan ku FDA pikeun tumor myofibroblastic radang ALK-positip
Juli 2022: Crizotinib (Xalkori, Pfizer Inc.) dipasihan persetujuan ku Administrasi Pangan sareng Narkoba (FDA) pikeun pengobatan pasien dewasa sareng murangkalih umur 1 taun sareng langkung lami anu didiagnosis teu tiasa direseksi, kambuh.
ALK, B7461006, crizotinib, Lorbrena, lorlatinib, NCT03052608, Pfizer, Ventana ALK, Sistem médis Ventana
Lorlatinib parantos disahkeun ku FDA pikeun pengobatan metastatik ALK-positip NSCLC.
Agustus 2021: Lorlatinib (Lorbrena, Pfizer Inc.) nampi persetujuan FDA rutin pikeun penderita kanker paru-paru sél alit metastatik (NSCLC) anu tumorna limfoma kinase anaplastic (ALK) -positif, sakumaha ditangtukeun ku aplikasi FDA ..
limfoma kinase anaplastik, B7461006, Uji CDx, Pangan sarta Narkoba Administrasi, Lorbrena, lorlatinib, NCT03052608, Nsclc, Pfizer, Ventana ALK, Sistem médis Ventana
Lorlatinib parantos disahkeun ku FDA pikeun pengobatan metastatik ALK-positip NSCLC
Agustus 2021: Lorlatinib (Lorbrena, Pfizer Inc.) nampi persetujuan FDA rutin pikeun penderita kanker paru-paru sél alit metastatik (NSCLC) anu tumorna limfoma kinase anaplastic (ALK) -positif, sakumaha ditangtukeun ku aplikasi FDA ..
Bharat Biotéh, Coronavirus, Kobékin, Covid, Vaksin covid, Kovishield, Pfizer
Vaksin COVID-19 - Sadaya anu anjeun hoyong terang
Dr. Julie Gralow ngajawab patarosan ngeunaan vaksin COVID-19. Kumaha urang tiasa mastikeun yén vaksin éta aman upami diproduksi sareng disatujuan dina waktos anu pondok?